Zoledronic Acid — Drug Monograph

Brand names: Zometa, Reclast (osteoporosis formulation — different dose/schedule)

Drug class: Supportive Care Agent

Mechanism of Action

Third-generation nitrogen-containing bisphosphonate with the highest potency of the bisphosphonate class. Binds with very high affinity to hydroxyapatite mineral surfaces in bone, concentrating at sites of active osteoclast-mediated bone resorption. Internalized by osteoclasts during bone resorption, where it inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate (cholesterol biosynthesis) pathway. FPPS inhibition depletes geranylgeranyl pyrophosphate (GGPP), blocking the geranylgeranylation of small GTPases (RhoA, Rac, Rab) essential for osteoclast cytoskeletal…

FDA Indications

• Hypercalcemia of malignancy (HCM): total calcium ≥12 mg/dL; Zometa 4 mg IV (superior to pamidronate — ZOMETA trial: greater complete response and faster normalization)
• Multiple myeloma and bone metastases from solid tumors (breast, prostate, NSCLC, renal): 4 mg IV every 3–4 weeks to prevent skeletal-related events (SREs: fracture, spinal cord compression, bone radiation/surgery need, hypercalcemia)

Common Side Effects

• Acute-phase reaction: fever, myalgia, arthralgia, headache, fatigue (20–30% with first infusion; decreases with subsequent doses; managed with acetaminophen ± NSAID)
• Nausea and vomiting
• Fatigue
• Hypocalcemia (must supplement calcium and vitamin D)
• Hypophosphatemia
• Hypomagnesemia
• Elevated serum creatinine (monitor before each dose)
• Elevated bone pain (transient post-infusion flare)

Clinical Pearl

ONJ is the most feared long-term complication — prevention is far easier than treatment. Always obtain a dental consultation and complete all necessary dental work BEFORE starting zoledronic acid; elective extractions, implants, and other invasive procedures should be deferred while on therapy. The acute-phase reaction to the first infusion (flu-like symptoms, bone pain) is largely preventable with prophylactic acetaminophen. Consider extending the dosing interval to every 12 weeks after 1–2…

Related Therapies & Mechanisms

• Aprepitant (Emend) — Supportive Care Agent
• Avatrombopag (Doptelet) — Supportive Care Agent
• Darbepoetin Alfa (Aranesp) — Supportive Care Agent
• Defibrotide (Defitelio) — Supportive Care Agent